Evaluating a new treatment for advanced solid tumors

An Open-Label, Phase 1/2 Study to Evaluate Safety, Efficacy, and Pharmacokinetics of EU101, an Agonistic Anti-CD137 (4-1BB) Monoclonal Antibody in Patients With Advanced Solid Tumors

This study is testing a new drug called EU101 to see if it is safe and effective for people with advanced solid tumors, particularly those with colorectal cancer and non-small cell lung cancer, who have run out of other treatment options.

Quick facts

• Phase: PHASE1; PHASE2
• Study type: Interventional
• Enrollment: 110 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Eutilex (industry)
• Drugs / interventions: cetuximab, panitumumab, bevacizumab, ramucirumab, chemotherapy
• Locations: 6 sites (Philadelphia, Pennsylvania and 5 other locations)
• Trial ID: NCT04903873 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to assess the safety, efficacy, and pharmacokinetics of a new drug, EU101, in patients with advanced solid tumors. The study is divided into two phases: Phase 1 focuses on determining the maximum tolerated dose and safety profile, while Phase 2 evaluates the drug's antitumor effects specifically in colorectal cancer and non-small cell lung cancer. Participants will be closely monitored for dose-limiting toxicities and overall treatment response. The trial includes patients who have exhausted standard treatment options or cannot receive them due to other medical conditions.

Who should consider this trial

Good fit: Ideal candidates include individuals with metastatic or locally advanced solid tumors that have not responded to standard therapies.

Not a fit: Patients with early-stage tumors or those who have not yet undergone standard treatment options may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with advanced solid tumors who have limited or no available treatments.

How similar studies have performed: Other studies evaluating similar approaches in advanced solid tumors have shown promising results, indicating potential for this treatment.

Eligibility criteria

Key Inclusion Criteria:

* Histologically or cytologically confirmed diagnosis of metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed because of disease progression or unacceptable toxicities. Also includes patients who cannot be treated with standard therapy because of underlying/existing medical condition.
* Cohort 1 (colorectal cancer): a) CRC (including microsatellite instability-high \[MSI-H\] and microsatellite-stable \[MSS\]) regardless of RAS mutation. b) Disease progression within 3 months after last administration of approved standard therapies. c) Prior cytotoxic chemotherapy for metastatic disease include all the following agents: fluoropyrimidine, oxaliplatin, and irinotecan
* Adjuvant chemotherapy-based treatments count as prior therapy, as long as relapse had occurred within 6 months of completion of such therapies, prior anti-epidermal growth factor receptor (EGFR) therapy (cetuximab, panitumumab), anti-angiogenic therapy (bevacizumab, aflibercept, ramucirumab), regorafenib, and TAS-102 are allowed. d) No more than 5 prior therapies for metastatic disease. For participants who had disease recurrence within 6 months of completing adjuvant chemotherapy, the adjuvant regimen can be considered as 1 chemotherapy regimen for metastatic disease
* Cohort 2 (NSCLC): a) NSCLC without known EGFR, anaplastic lymphoma kinase (ALK), and ROS1 genomic tumor aberrations. b) No standard therapy exists or standard therapy has failed. c) No more than 3 prior therapies for metastatic disease
* Phase 2: At least 1 measurable lesion per RECIST version 1.1
* Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2
* Adequate organ and bone marrow function (Hemoglobin \>9.0 g/dL, Absolute neutrophil count ≥1,500/μL, Absolute lymphocyte count ≥600 and ≤2,500/μL, Platelet count ≥100,000/μL, Total bilirubin ≤1.5 × upper limit of normal, Alanine aminotransferase and aspartate aminotransferase ≤2.5 × ULN, Serum creatinine ≤1.5 × ULN or creatinine clearance \>30 mL/min, Prothrombin time and activated partial thromboplastin time ≤1.5 × ULN)
* Life expectancy of at least 12 weeks
* Voluntarily provided a written consent to participate in the study
* Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within the 7 days before study drug administration
* WOCBP and sexually active fertile male patients with partners who are WOCBP must agree to use 2 highly effective methods of contraception throughout the course of the study and for 12 weeks after the last dose of study drug.

Key Exclusion Criteria:

* Primary central nervous system (CNS) tumor (Phase 1), CNS metastasis, and/or carcinomatous meningitis. Participants with prior brain metastases treated at least 4 weeks before the first dose of EU101 that are clinically stable and do not require chronic corticosteroid treatment are allowed. Untreated but asymptomatic and clinically stable brain metastases per investigator's discretion are allowed
* Received prior therapy with any anti-CD137 monoclonal antibody (mAb) or agent
* Major surgery requiring general anesthesia within 3 weeks before first dose of EU101 or still recovering from prior surgery
* Active infection that is not controlled or requires intravenous antibiotics in the last 2 weeks
* History of allogeneic tissue or organ transplant
* Active hepatitis B virus or hepatitis C virus infection
* History of any noninfectious hepatitis
* Human immunodeficiency virus (HIV) infection
* Received or receiving systemic corticosteroid therapy or any other form of systemic immunosuppressive medicaion 1 week before first dose of EU101
* Known severe (≥Grade 3) hypersensitivity reactions to antibody, or severe reaction to immuno-oncology agents requiring treatment with steroids
* Konwn or suspected hypersensitivity to EU101 or any component of its formulation
* Current or history of interstitial lung disease, anaphylaxis, uncontrolled asthma, or pneumonitis that has required systemic corticosteroids
* Patients with second primary cancer
* Clinically significant concurrent cardiovascular disease
* Pregnant women, breasfeeding women, WOCBP, or men with partners who are WOCBP who do not agree to use adequate contraceptive measures
* Determined as unable to participate in the study per investigator's judgment

Other protocol defined Inclusion/Exclusion criteria may apply

Where this trial is running

Philadelphia, Pennsylvania and 5 other locations

• Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States (RECRUITING)
• Mary Crowley Center — Dallas, Texas, United States (RECRUITING)
• National Cancer Center — Ilsan, Korea, Republic of (NOT_YET_RECRUITING)
• Samsung Seoul Hospital — Seoul, Korea, Republic of (RECRUITING)
• Seoul Asan — Seoul, Korea, Republic of (RECRUITING)
• Severance Hospital — Seoul, Korea, Republic of (RECRUITING)

Study contacts

• Study coordinator: Seoyoun Kim, MPH

Conditions: Solid Tumor, Renal Cell Cancer Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Prostate Cancer, Dose Escalation, Maximum tolerated dose